Erlotinib is an EGFR tyrosine kinase inhibitor that has been authorized by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung cancer (NSCLC) and pancreatic cancer. Here, EGFR is linked to non-small cell lung carcinoma.